Phase 1 Parkinson's Disease Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have an advanced solid tumour (one that has spread to other parts of the body or cannot be surgically removed), confirmed by laboratory testing of tissue or cells.
• People who have already received at least one prior cancer treatment for the disease being studied in this trial.
• People whose doctor considers a single immunotherapy drug to be an appropriate treatment option for them.
• People who are reasonably active and able to care for themselves, with an Eastern Cooperative Oncology Group (ECOG) fitness score of 0 or 1 at the time of joining, with no recent decline in that score (confirm with trial site).
• People who have a life expectancy of at least 12 weeks at the time of joining.
• People whose liver, kidneys, bone marrow, and other organs are functioning adequately (confirm with trial site for specific requirements).
• People who weigh at least 30 kg.

Who may not be able to join:

• People with severe or poorly controlled serious illnesses that could make participation unsafe or interfere with following the trial's requirements.
• People who have previously had an organ transplant.
• People who have had another separate cancer that was active at any point in the last 2 years.
• People who still have significant side effects from a previous cancer treatment (other than hair loss) that have not returned to a mild level or back to their pre-treatment baseline.
• People with unstable or symptomatic cancer spread to the brain, or with compression of the spinal cord.
• People who have had cancer spread to the membranes surrounding the brain or spinal cord.
• People with an active immune deficiency condition, or active infections including tuberculosis (TB), HIV, or hepatitis A, B, or C.
• People with a history of significant heart rhythm problems, heart muscle disease, symptomatic heart failure, or a heart attack within the past 6 months.
• People with poorly controlled ongoing illnesses, including active infections, lung scarring or inflammation (interstitial lung disease), serious gut conditions involving chronic diarrhoea, or active non-infectious skin conditions requiring systemic treatment.
• People with active or previously diagnosed autoimmune or inflammatory conditions that have required ongoing treatment with steroids or other immune-suppressing medications.
• People with a known allergy or sensitivity to the study drug (rilvegostomig), hyaluronidase, or any of the other ingredients in the study medications.
• People who previously had to permanently stop an immunotherapy treatment due to serious side effects from that treatment.
• People who have received any prior cancer treatment, including immunotherapy, within 28 days before the first planned dose of the study treatment.

Important: Always verify eligibility with the trial site directly before applying.